InnovAge vs P3 Health Partners
INNV and PIII side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How INNV and PIII compare
InnovAge is the larger company, worth 66 times as much as P3 Health Partners ($1.3B against $19.6M).
InnovAge grew revenue faster over the last twelve months (15.9% versus 7.5% for P3 Health Partners).
InnovAge keeps more of each dollar of sales as profit, with a net margin of −0.26% compared with −3.3% at P3 Health Partners.
InnovAge scores higher on the StockData Score (10 against 4 for P3 Health Partners), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | INNV | PIII |
|---|---|---|
| Size and price | ||
| Market cap | $1.3B | $19.6M |
| Share price | $9.47 | $2.70 |
| Change, 1 year | 66.4% | −64.6% |
| Change, 5 years | 12.6% | −99.5% |
| Beta (5Y) | 0.68 | 1.16 |
| Employees | 2,500 | 320 |
| StockData Score | ||
| Total score | 10 (better) | 4 |
| Valuation score | 0 | 1 (better) |
| Growth score | 3 (better) | 1 |
| Performance score | 2 | 2 |
| Health score | 5 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.3× | 0.0× (better) |
| P/B | 5.5× | – |
| EV/EBITDA | 50.6× | 36.9× (better) |
| P/FCF | 25.6× | – |
| FCF yield | 3.9% | – |
| Fair value | $5.76 | – |
| Margin of safety | −64.3% | – |
| Growth | ||
| Revenue growth (TTM) | 15.9% (better) | 7.5% |
| Revenue growth, 5Y average | 9.2% | 24.3% (better) |
| Profitability | ||
| Gross margin | 23.0% | – |
| Operating margin | 0.26% (better) | −5.2% |
| Net margin | −0.26% (better) | −3.3% |
| FCF margin | 5.1% | – |
| Return on equity | −1.1% | – |
| Return on invested capital | 1.2% (better) | −32.7% |
| Financial health | ||
| Debt / equity | 0.20 | – |
| Net debt / EBITDA | −3.93 | 28.58 (better) |
| Current ratio | 1.05 (better) | 0.53 |
| Altman Z-score | 4.23 (better) | 0.29 |
| Piotroski F-score | 6 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 13.5% | 65.0% |
| Held by insiders | 75.4% | 98.0% |
| Insider net buying, 12 months | −$227M | −$824K (better) |
| Short interest, % of float | 2.7% | – |
Go deeper
- INNV stock overview
- INNV income statement
- INNV valuation and score
- PIII stock overview
- PIII income statement
- PIII valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.